IL6 and congestive heart failure: Clinical investigations have demonstrated that TGP effectively suppresses inflammation in stable CHF patients by reducing the release of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) [20].